Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Kingsley Hampton, Pratima Chowdary, Scott Dunkley, Silke Ehrenforth, MD PhD, Lotte Jacobsen, Anne T. Neff, MD, Elena Santagostino, MD PhD, Jameela Sathar, Hideyuki Takedani, Clifford M. Takemoto, MD, Claude Négrier

Blood (2015) 126 (23): 2283.

https://doi.org/10.1182/blood.V126.23.2283.2283

Published: 2015

Journal Articles

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors

Erich de Paula, Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, László Nemes, Silva Zupancic Salek, Midori Shima, Jerzy Windyga, Silke Ehrenforth, Henning Friis Andersen, Ampaiwan Chuansumrit, and on behalf of 1804 (ADEPT-1) Investigators

Blood (2010) 116 (21): 719.

https://doi.org/10.1182/blood.V116.21.719.719

Published: 2010

Journal Articles

rFVIIa Treatment and Efficacy Prediction in a Patient with Hermansky-Pudlak Syndrome Type 1 (HPS-1) Using Global Clotting Tests and Flow Cytometry.

Wolfgang Wegert, MSc, Thomas Scholz, Eng., Silke Ehrenforth, MD, Wolfgang Mondorf, MD, Carl M. Kirchmaier, MD

Blood (2005) 106 (11): 4019.

https://doi.org/10.1182/blood.V106.11.4019.4019

Published: 2005

Journal Articles

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors

Ulrike Nowak-Göttl, Ralf Junker, Wolfhart Kreuz, Arnold von Eckardstein, Andrea Kosch, Natascha Nohe, Rosemarie Schobess, Silke Ehrenforth

Blood (2001) 97 (4): 858–862.

https://doi.org/10.1182/blood.V97.4.858

Published: 2001

Journal Articles

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism

Mario von Depka, Ulrike Nowak-Göttl, Roswith Eisert, Christian Dieterich, Monika Barthels, Inge Scharrer, Arnold Ganser, Silke Ehrenforth

Blood (2000) 96 (10): 3364–3368.

https://doi.org/10.1182/blood.V96.10.3364

Published: 2000

Journal Articles

Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors

Ulrike Nowak-Göttl, Cornelia Wermes, Ralf Junker, Hans-Georg Koch, Rosmarie Schobess, Gudrun Fleischhack, Dirk Schwabe, Silke Ehrenforth

Blood (1999) 93 (5): 1595–1599.

https://doi.org/10.1182/blood.V93.5.1595

Published: 1999

NARROW

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors

rFVIIa Treatment and Efficacy Prediction in a Patient with Hermansky-Pudlak Syndrome Type 1 (HPS-1) Using Global Clotting Tests and Flow Cytometry.

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism

Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors

Email alerts

ASH Publications

American Society of Hematology

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors

rFVIIa Treatment and Efficacy Prediction in a Patient with Hermansky-Pudlak Syndrome Type 1 (HPS-1) Using Global Clotting Tests and Flow Cytometry.

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism

Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only